Walgreens Teams Up with Workflow Services to Enhance Colorectal Cancer Screening Accessibility
In a significant move aimed at bolstering health initiatives, Walgreens has launched a program in collaboration with Workflow Services and Exact Sciences to enhance colorectal cancer screening options for its customers. The initiative will provide individuals with vital resources to understand their screening choices better, utilizing the Cologuard® test for eligible patients at average risk. This partnership comes at a crucial time, coinciding with Colorectal Cancer Awareness Month, where the focus is on removing barriers to screening and facilitating early detection, critical for effective treatment.
Colorectal cancer remains a leading cause of cancer-related fatalities, especially among adults under 50 years of age, claiming over 55,000 lives across the U.S. in a single year. The disease is notorious for being silent, often developing without visible symptoms. Despite its preventable nature, more than one-third of U.S. adults are not current with their colorectal screening, highlighting a critical gap in health awareness that this initiative seeks to address. The Cologuard test—a non-invasive stool DNA test approved by the FDA—offers a convenient screening alternative for individuals 45 and older, needing no special diet or preparation.
According to Rick Gates, Walgreens' Chief Pharmacy Officer, this initiative is a testament to the community's health commitment. "As a trusted health partner, we aim to change the trajectory of this disease by giving patients educational resources regarding their colon cancer screening options, empowering them to take proactive steps toward their health.", he stated. By seamlessly integrating this screening program into pharmacy operations, Walgreens helps patients access vital health services conveniently, in a familiar environment.
Workflow Services plays a pivotal role in this collaboration, utilizing its pharmacy clinical workflow platform to support the implementation of these programs on a national scale. This partnership not only enables pharmacists to provide better care but also improves communication between patients, healthcare providers, and insurers. With preventive screenings, Walgreens can effectively bridge the gap between patients and crucial healthcare resources, reinforcing its mission to improve health outcomes across communities.
Jake Orville, Executive Vice President of Screening at Exact Sciences, expressed pride in supporting Walgreens in this endeavor. Through increased screening rates enabled by products like Cologuard, they aim to elevate patient access to important health interventions, ensuring that screenings are accessible at local pharmacies, a setting patients are comfortable in.
The focus on preventive measures in healthcare has never been more crucial, particularly for conditions like colorectal cancer, where early detection can lead to much higher survival rates. Statistics show that when identified in its early stages, the five-year survival rate for colorectal cancer can reach up to 91%.
For patients interested in learning more about the Cologuard test and available colorectal cancer screening options, Walgreens provides resources through its platforms. Both Walgreens and Exact Sciences emphasize this initiative being not only a healthcare service but a community-driven effort aiming to reduce the prevalence of colorectal cancer through education and accessible care initiatives.
As the landscape of pharmacy care continues to evolve, collaborations such as this not only enrich the service offerings at pharmacies but also contribute significantly to public health objectives. By prioritizing preventive screenings and awareness campaigns, Walgreens, Workflow Services, and Exact Sciences collectively work towards a healthier future for individuals, reinforcing the importance of proactive health management.
In conclusion, Walgreens’ initiative to enhance colorectal cancer screening availability through collaboration with Workflow Services and Exact Sciences isn't merely about providing a test; it’s about making a lasting impact on public health by ensuring everyone has the chance to act upon their health proactively, thereby saving lives and fostering healthier communities.
Colorectal cancer remains a leading cause of cancer-related fatalities, especially among adults under 50 years of age, claiming over 55,000 lives across the U.S. in a single year. The disease is notorious for being silent, often developing without visible symptoms. Despite its preventable nature, more than one-third of U.S. adults are not current with their colorectal screening, highlighting a critical gap in health awareness that this initiative seeks to address. The Cologuard test—a non-invasive stool DNA test approved by the FDA—offers a convenient screening alternative for individuals 45 and older, needing no special diet or preparation.
According to Rick Gates, Walgreens' Chief Pharmacy Officer, this initiative is a testament to the community's health commitment. "As a trusted health partner, we aim to change the trajectory of this disease by giving patients educational resources regarding their colon cancer screening options, empowering them to take proactive steps toward their health.", he stated. By seamlessly integrating this screening program into pharmacy operations, Walgreens helps patients access vital health services conveniently, in a familiar environment.
Workflow Services plays a pivotal role in this collaboration, utilizing its pharmacy clinical workflow platform to support the implementation of these programs on a national scale. This partnership not only enables pharmacists to provide better care but also improves communication between patients, healthcare providers, and insurers. With preventive screenings, Walgreens can effectively bridge the gap between patients and crucial healthcare resources, reinforcing its mission to improve health outcomes across communities.
Jake Orville, Executive Vice President of Screening at Exact Sciences, expressed pride in supporting Walgreens in this endeavor. Through increased screening rates enabled by products like Cologuard, they aim to elevate patient access to important health interventions, ensuring that screenings are accessible at local pharmacies, a setting patients are comfortable in.
The focus on preventive measures in healthcare has never been more crucial, particularly for conditions like colorectal cancer, where early detection can lead to much higher survival rates. Statistics show that when identified in its early stages, the five-year survival rate for colorectal cancer can reach up to 91%.
For patients interested in learning more about the Cologuard test and available colorectal cancer screening options, Walgreens provides resources through its platforms. Both Walgreens and Exact Sciences emphasize this initiative being not only a healthcare service but a community-driven effort aiming to reduce the prevalence of colorectal cancer through education and accessible care initiatives.
As the landscape of pharmacy care continues to evolve, collaborations such as this not only enrich the service offerings at pharmacies but also contribute significantly to public health objectives. By prioritizing preventive screenings and awareness campaigns, Walgreens, Workflow Services, and Exact Sciences collectively work towards a healthier future for individuals, reinforcing the importance of proactive health management.
In conclusion, Walgreens’ initiative to enhance colorectal cancer screening availability through collaboration with Workflow Services and Exact Sciences isn't merely about providing a test; it’s about making a lasting impact on public health by ensuring everyone has the chance to act upon their health proactively, thereby saving lives and fostering healthier communities.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.